The National Comprehensive Cancer Network (NCCN) has reported that despite the FDA's efforts, chemo shortages persist stating that many treatment centers are lacking supplies of key medicines.

NCCN surveyed 29 of its member institutions throughout the month of September and found that 72% of centers are still experiencing a carboplatin shortage, while 59% are short on cisplatin.

This is a follow-up to a June survey that showed 93% of centers were experiencing a carboplatin shortage, while 70% were low on cisplatin.

Nearly all of the centers surveyed are able to treat patients with a carboplatin or cisplatin regimen by following strict waste management strategies.

Click here to read the entire article.